Characterization of the function of Adenovirus L4 gene products and their impact on AAV vector production
Efficient manufacturing of recombinant adenovirus-associated virus (AAV) vectors is critical to the successful development of genomic medicines. We attempted to optimize AAV vector production in a producer cell line platform. In this system, helper functions required for AAV replication and production are provided via infection with a replication-competent wild-type Adenovirus. To evaluate strategies for the reduction of replication and packaging of adenovirus and to understand the interplay of recombinant AAV and the helper virus during AAV vector production, wild-type adenovirus was compared to a mutant (Ad5ts149) containing a temperature-sensitive mutation in the DNA polymerase gene. Infection of a producer cell line with Ad5ts149 at the restrictive temperature reduced recombinant AAV titer and altered the pattern of AAV protein expression. Further investigation revealed that the adenoviral late L4-22K/33K gene products regulated both AAV <i>rep/cap</i> gene transcription and splicing of the <i>rep/cap</i> transcripts. Furthermore, the L4-33K gene products were found to impact AAV production in both the producer cell line and transient transfection platforms. Optimization of Adenovirus L4-22K/33K expression to facilitate efficient expression and splicing of AAV <i>rep/cap</i> transcripts therefore represents a unique opportunity to optimize AAV vector production.
Authors
- Bruno Figueroa
- Huimin Na (ORCID: https://orcid.org/0000-0002-7062-6813)
- Yingchao Nie (ORCID: https://orcid.org/0000-0001-6151-0811)
- Qingliang Li (ORCID: https://orcid.org/0000-0002-6453-236X)
- Hao Pan (ORCID: https://orcid.org/0000-0003-2709-1494)
- Karen A. Vincent
Institutions
- Center for Genomic Science (IT)
Publication Details
- Journal
- Molecular Therapy — Methods & Clinical Development
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1016/j.omtm.2024.101370
- Citations
- 2
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.10
Funders
- Sanofi
- Sanofi Genzyme